Halozyme Therapeutics Sees FY25 EPS $4.10–$4.50, Revenue $1.04B–$1.115B; FY26 EPS $5.30–$5.80, Revenue $1.265B–$1.365B; FY27 EPS $6.70–$7.30, Revenue $1.515B–$1.64B; FY28 EPS $6.90–$7.50, Revenue $1.565B–$1.690B
Benzinga Newsdesk - Jan 17, 2024, 1:06PM